“Landmark victory.” “Life-changing.” “Transformative.” “Paradigm shift.” Potentially “revolutionary.” Those upbeat descriptions appeared in headlines about the sickle cell drug Oxbryta (voxelotor) before it was abruptly pulled from the market in late September due to safety concerns.  Pfizer’s decision to withdraw the drug — citing an “imbalance” of complications and deaths in patients who were taking…